Connected Health

Our goal is to innovate across our digital health platforms by using the vast amount of data that we collect, in combination with technology such as artificial intelligence or machine leaning, to provide information and insights to people living with diabetes their healthcare providers and to insurance payors. Key areas of development include making these insights easy to understand, provided in a flexible format with mobile or cloud apps, and available in real time. In addition, we are working to support integration with other health-related information from third-party sources, and support for future products under development.

Tandem Source

Expanding the capabilities of our domestic t:connect data management application, Tandem Source is our second-generation web-based data management application that’s being designed for global use. This application provides added interface customizability and provides opportunities for customers to personalize how they engage with their data and for healthcare providers to manage their care. In the second quarter of 2021, we began limited testing of an initial version of Tandem Source in the United Kingdom.

Next Generation Pumps

Mobi Insulin Pump

Approximately half the size of our t:slim X2 pump, the Tandem Mobi is being designed for people who seek even greater discretion and flexibility with the use of their insulin pump. Its features include a 200-unit cartridge, an on-pump bolus button, inductive charging, an AID algorithm, and is waterproof. We anticipate that Mobi will be our first insulin pump to support full pump-control from our mobile application.

t:slim X3 Insulin Pump

Advancing our flagship t:slim platform, the t:slim X3 is being designed to provide a modernized user interface and even greater usability for our planned feature updates. It’s also being designed to include enhanced technology, such as greater processing power and capacity to support our advanced algorithms, as well as increased battery life, improved durability, and wireless software update capabilities.

Mobi Insulin Pump (Tubeless)

This offering is being developed to provide an alternative tubeless infusion site option for Mobi pump users. A goal of this design is to allow for people living with diabetes to customize the way they wear their pump with each cartridge change to best suit their personal preferences and lifestyle.

Patch

Our patch pump design is in its early stages and is being developed for the segment of the people living with diabetes who want a disposable tubeless solution. In its design, we are seeking to drive further miniaturization, potentially with concentrated insulins.

Algorithm Enhancements

Our device software is used to control our pumps either directly through the pump’s interface or through our mobile application. It also includes our automated insulin delivery technology, and the software used to support remote pump updatability.

Control-IQ Technology Advancements

We are driving innovation in our algorithms, emphasizing automation, personalization, and simplification, all intended to continue to improve therapeutic outcomes and provide a positive patient experience characterized by simplicity and ease of use. Examples of our efforts to provide enhanced personalization include alternative targets, settings optimizations, and enhanced exercise options. Examples of our efforts to provide greater ease of use include adaptations, smarter alerts, and new signal integrations. In addition, we anticipate pursuing the initiation and design of clinical research to support potential expanded Control-IQ technology indications for people with type 1 ages 2 to 5 years old, as well as people living with type 2 diabetes. We are also researching the use of different insulins with our Control-IQ technology, including ultra-rapid insulins, concentrated insulins, and generic insulins.

Mobile Control

Our Tandem t:slim mobile app provides users with a convenient and discreet data display and alerts on their iOS and Android phones, and functions as a pipeline for getting pump data to the cloud. In the 4th quarter of 2020, we submitted a regulatory filing to the FDA for a mobile bolus delivery feature that will allow t:slim X2 pump users to control a bolus of insulin using our app. Subject to regulatory review and approval, in the future this app is also planned to include additional pump control features, such as full operation of our Mobi pump.